Title: Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial
Authors: Finke, Jürgen ×
Schmoor, Claudia
Bethge, Wolfgang A
Ottinger, Hellmut D
Stelljes, Matthias
Zander, Axel R
Volin, Liisa
Heim, Dominik A
Schwerdtfeger, Rainer
Kolbe, Karin
Mayer, Jiri
Maertens, Johan A
Linkesch, Werner
Holler, Ernst
Koza, Vladimir
Bornhäuser, Martin
Einsele, Hermann
Bertz, Hartmut
Grishina, Olga
Socié, Gérard
ATG-Fresenius Trial Group
Verhoef, Gregor #
Issue Date: Nov-2012
Publisher: Kluge Carden Jennings Pub. Co.
Series Title: Biology of Blood and Marrow Transplantation vol:18 issue:11 pages:1716-1726
Article number: 10.1016/j.bbmt.2012.06.001
Abstract: Several prognostic factors for the outcome after allogeneic hematopoietic stem-cell transplant (HSCT) from matched unrelated donors have been postulated from registry data; however, data from randomized trials are lacking. We present analyses on the effects of patient-related, donor-related, and treatment-related prognostic factors on acute GVHD (aGVHD), chronic GVHD (cGVHD), relapse, nonrelapse mortality (NRM), disease-free survival (DFS), and overall survival (OS) in a randomized, multicenter, open-label, phase III trial comparing standard graft-versus-host-disease (GVHD) prophylaxis with and without pretransplantation ATG-Fresenius (ATG-F) in 201 adult patients receiving myeloablative conditioning before HSCT from HLA-A, HLA-B antigen, HLA-DRB1, HLA-DQB1 allele matched unrelated donors. High-resolution testing (allele) of HLA-A, HLA-B, and HLA-C were obtained after study closure, and the impact of an HLA 10/10 4-digit mismatch on outcome and on the treatment effect of ATG-F versus control investigated. Advanced disease was a negative factor for relapse, DFS, and OS. Donor age ≥40 adversely affected the risk of aGVHD III-IV, extensive cGVHD, and OS. Younger donors are to be preferred in unrelated donor transplantation. Advanced disease patients need special precautions to improve outcome. The degree of mismatch had no major influence on the positive effect of ATG-F on the reduction of aGVHD and cGVHD.
ISSN: 1083-8791
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Cell and Gene Therapy Applications (-)
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science